中国医学创新2025，Vol.22Issue(7)：19-23,5.DOI:10.3969/j.issn.1674-4985.2025.07.005
沙库巴曲缬沙坦钠在血液透析合并慢性心衰患者中的临床疗效研究
Clinical Efficacy of Sacubitril Valsartan Sodium in Hemodialysis Patients Complicated with Chronic Heart Failure
摘要
Abstract
Objective:To evaluate the clinical efficacy of Sacubitril Valsartan Sodium in hemodialysis patients with chronic heart failure(CHF).Method:A total of 103 hemodialysis patients with CHF treated in Xinyu People's Hospital from October 2022 to October 2023 were selected and divided into observation group(n=55)and control group(n=48)according to random number table method.Both groups received conventional treatment,the control group received Valsartan treatment,and the observation group received Sacubitril Valsartan Sodium treatment.Cardiac function index,renal function index,inflammatory factor level and drug safety between the two groups before treatment and 6 months after treatment were compared.Result:Before treatment,there were no significant differences in cardiac function indexes,renal function indexes and inflammatory factors between the two groups(P>0.05).After 6 months of treatment,left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)in observation group were lower than those in control group,and left ventricular ejection fraction(LVEF)was higher than that in control group,the differences were statistically significant(P<0.05).After 6 months of treatment,the levels of blood urea nitrogen(BUN)and serum creatinine(Scr)in observation group were lower than those in control group,the differences were statistically significant(P<0.05).After 6 months of treatment,the levels of C reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in observation group were lower than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions and adverse cardiovascular events between the two groups(P>0.05).Conclusion:The application of Sacubitril Valsartan Sodium in hemodialysis patients with CHF has positive effects,which is conducive to improving the cardiac and renal function of patients,promoting the alleviation of inflammatory symptoms,thus improving the efficacy and having a high safety.关键词
沙库巴曲缬沙坦钠/血液透析/慢性心力衰竭/心功能/肾功能Key words
Sacubitril Valsartan Sodium/Hemodialysis/Chronic heart failure/Heart function/Renal function引用本文复制引用
李细女,敖辉平,康文龄,蒋芳,刘桃英..沙库巴曲缬沙坦钠在血液透析合并慢性心衰患者中的临床疗效研究[J].中国医学创新,2025,22(7):19-23,5.基金项目
新余市科技计划项目(2033090808) （2033090808）
